Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Long-Term Investments (2019 - 2022)

Historic Long-Term Investments for China SXT Pharmaceuticals (SXTC) over the last 4 years, with Q3 2022 value amounting to $1.6 million.

  • China SXT Pharmaceuticals' Long-Term Investments changed 0.0% to $1.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.6 million for FY2022, which is 0.0% changed from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Long-Term Investments stood at $1.6 million for Q3 2022, which was down 0.0% from $1.6 million recorded in Q1 2022.
  • In the past 5 years, China SXT Pharmaceuticals' Long-Term Investments ranged from a high of $1.6 million in Q3 2020 and a low of -$3.6 million during Q3 2019
  • In the last 4 years, China SXT Pharmaceuticals' Long-Term Investments had a median value of $1.6 million in 2021 and averaged $840764.9.
  • Its Long-Term Investments has fluctuated over the past 5 years, first skyrocketed by 14449.18% in 2020, then crashed by 167.91% in 2021.
  • Quarter analysis of 4 years shows China SXT Pharmaceuticals' Long-Term Investments stood at -$3.6 million in 2019, then soared by 144.49% to $1.6 million in 2020, then fell by 1.68% to $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022.
  • Its Long-Term Investments was $1.6 million in Q3 2022, compared to $1.6 million in Q1 2022 and $1.6 million in Q3 2021.